Last reviewed · How we verify
FL058 1000mg( IV 120min) — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
FL058 1000mg( IV 120min) (FL058 1000mg( IV 120min)) — Qilu Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FL058 1000mg( IV 120min) TARGET | FL058 1000mg( IV 120min) | Qilu Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FL058 1000mg( IV 120min) CI watch — RSS
- FL058 1000mg( IV 120min) CI watch — Atom
- FL058 1000mg( IV 120min) CI watch — JSON
- FL058 1000mg( IV 120min) alone — RSS
Cite this brief
Drug Landscape (2026). FL058 1000mg( IV 120min) — Competitive Intelligence Brief. https://druglandscape.com/ci/fl058-1000mg-iv-120min. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab